Skip to main content
SpringerLink
Log in

Introduction: The Enigma of Tamoxifen

  • Chapter
Tamoxifen

Abstract

The antiestrogen effect of Tamoxifen remains the basic rationale for its general acceptance and wide use. Estrogens play a definite role in the etiology and growth of a variety of cancers, including the breast, endometrium, prostate and probably others; interference with their action, prevention of estrogen effects, has been a promising goal long before the introduction of chemical castration by antiestrogens. However, the straightforward interpretation that antiestrogens operate by competitive binding to estrogen receptors alone had soon to be abandoned. Tamoxifen was found to be cytocidal at high concentrations and tumoristatic at serum levels achievable in vivo. The evaluation of physiological and pharmacological actions of Tamoxifen in humans is an increasingly complex issue, not in the least because of its mixed estrogen agonistic and antagonistic effects.

“To single out causes, one must make loose assumptions” (G.B. Levy, 1995)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

References

  • Ahotupa M, Hirsimä P, Pärssinen R, Mantyla E (1994): Alternations of drug metabolizing and antioxidant enzyme activities during tamoxifen- induced hepatocarcinogenesis in the rat.Carcinogenesis 15:863–868

    Article  PubMed  CAS  Google Scholar 

  • Akeli MG, Madoulet C, Rallet A, Jardillier JC (1991): Inhibition of collagenolytic activity in human leukemic K563 cells by tamoxifen. Leukemia Res 15:1153–1157

    Article  CAS  Google Scholar 

  • Anja S, Shekar GC, Rao DR, Mohandas S (1993): Superior ophthalmic vein thrombosis with tamoxifen.Can J Neurol Sci 20:SI97

    Google Scholar 

  • Anker G, Loenning PE, Ueland PM, Refsum H, Lien EA (1993): Tamoxifen suppresses the plasma level of atherogenic factor homocysteine. Europ J Cancer 29A:S110

    Article  Google Scholar 

  • Antoniuk P, Tjandra JJ, Lavery IC (1993): Diffuse intra-abdominal fibromatosis in association with bilateral ovarian fibromatosis and oedema. Austral New Zealand J Surg 63:315–318

    Article  CAS  Google Scholar 

  • Beggs WH (1994): Comparative activities of miconazole and the anticancer drug tamoxifen against Candida albicans. J Antimicrob Chemother 34:186–187

    Article  PubMed  CAS  Google Scholar 

  • Beggs WH (1995): Growth phase in relation to the lethal action of tamoxifen on Candida albicans. Res Com Mol Path Pharmacol 88:115–117

    CAS  Google Scholar 

  • Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V (1994): Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype.Cancer Res 54:4607–4609

    PubMed  CAS  Google Scholar 

  • Butta A, MacLennan K, Flanders KC, Sacks PM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta A A (1992): Induction of transforming growth factor betal in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52:4261–4264

    PubMed  CAS  Google Scholar 

  • Carthew P, Martin EA, White INH, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL (1995): Tamoxifen Induced Short-Term Cumulative DNA Damage and Liver Tumors in Rats: Promotion by Phenobarbital. Cancer Res 55:544–547

    PubMed  CAS  Google Scholar 

  • Chern S and Danis RP (1993): Retinopathy associated with low-dose tamoxifen. Am J Ophthal 116:372–373

    PubMed  CAS  Google Scholar 

  • Clarke R, van den Berg HW, Murphy RF (1990): Reduction of the Membrane Fluidity of Human Breast Cancer Cells by Tamoxifen and 17beta- Estradiol. J Natl Cancer Inst 82:1702–1705

    Article  PubMed  CAS  Google Scholar 

  • Cohen FJ, Manni A, Glikman P, Bartholomew M, Demers L (1988): Involvement of the Polyamine Pathway in Antiestrogen-induced Growth Inhibition of Human Breast Cancer. Cancer Res 48:6819–6825

    PubMed  CAS  Google Scholar 

  • Coradini D, Biffi A, Pirronella E, Di Fronzo G (1995): Tamoxifen and betaInterferon: Effect of Simultaneous or Sequential Treatment on Breast Cancer Cell Lines. Anticancer Res 15:315–320

    PubMed  CAS  Google Scholar 

  • Creamer P, Lim K, George E, Dieppe P (1994): Acute inflammatory polyarthritis in association with tamoxifen.Brit J Rheumatol 33:583–585

    Article  CAS  Google Scholar 

  • Cutuli B, Abecassis J, Petit JC, Fricker JC, Schumacher C, Jung GM, Velten M (1993): Thromboembolic accidents in postmenopausal women treated by adjuvant Tamoxifen: 19 case reports. Europ J Cancer 29A:S72

    Article  Google Scholar 

  • Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V, Pemberton K, Pitt P, Richmond W, Houghton J, Riley D (1993): Long Term Effects of Tamoxifen. Europ J Cancer 29A: 15–21

    Article  Google Scholar 

  • Dreicer R and Wilding G (1992): Steroid Hormone Agonists and Antagonists in the Treatment of Cancer. Cancer Invest 10:27–41

    Article  PubMed  CAS  Google Scholar 

  • Fernö M, Baldetorp B, Borg A, Brouillet JP, Olsson H, Rochefort H, Sellberg G, Sigurdson H, Killander D (1994): Cathepsin D, Both a Prognostic Factor and a Predictive Factor for the Effect of Adjuvant Tamoxifen in Breast Cancer. Europ J Cancer 30A:2042–2048

    Article  Google Scholar 

  • Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H, Klijn JGM (1995): Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer. J Natl Cancer Inst 87:751–756

    Article  PubMed  CAS  Google Scholar 

  • Friedman ZY (1994): The Antitumour Agent Tamoxifen Inhibits Breakdown of Polyphosphoinositides in GH4C1 Cells.J Pharmacol Experim Therapeut 271:238–245

    CAS  Google Scholar 

  • Garcia-Ruiz N, Sanchez MC, Valenzuela P, Jimenez P, Rodriguez E, Cortes-Prieto J (1994): Ocular toxicity of tamoxifen: a case of optic neuritis. Oncologic (Madrid) 17:64–66

    Google Scholar 

  • Gong Y, Ballejo G, Murphy LC, Murphy LK (1992): Differential Effects of Estrogen and Antiestrogen on Transforming Growth Factor Gene Expression in Endometrial Adenocarcinoma Cells. Cancer Res 52:1704–1709

    PubMed  CAS  Google Scholar 

  • Gottardis MM, Robinson SP, Satyaswaroop PG (1988): Contrasting actions of tamoxifen on endometrial and breast tumour growth in athymic mouse. Cancer Res 48:812–815

    PubMed  CAS  Google Scholar 

  • Hampson JP, Donnelly A, Lewis-Jones MS, Pye JK (1995): Tamoxifen-induced hair colour change. Brit J Dermatol 132:483–484

    Article  CAS  Google Scholar 

  • Heier JS, Dragoo RA, Enzenhauer RW, Waterhouse WJ (1994): Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Amer J Ophthal 117:772–775

    PubMed  CAS  Google Scholar 

  • Jacquemiere J, Penault-Llorca F, Viens P, Houveenaeghel G, Hassouni J, Torrente M, Adelaide J, Birnbaum D (1994): Breast Cancer Response to Adjuvant Chemotherapy in Correlation with erbB2 and p53 Expression. Anticancer Res 14:2273–2278

    Google Scholar 

  • Johnston SRD, McLennan KA, Salter J, Sacks NM, McKinna JA, Baum M, Smith IE, Dowsett M (1993): Tamoxifen induced the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in vivo. The Breast 2:93–99

    Google Scholar 

  • Jordan VC (1995a): Tamoxifen and Tumorigenicity: a Predictable Concern.J Natl Cancer Inst 87:623–626

    Article  PubMed  CAS  Google Scholar 

  • Jordan VC (1995b): What if tamoxifen (ICI 46, 474) had been found to produce rat liver tumors in 1993? Ann Oncol 87:623–626

    CAS  Google Scholar 

  • Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF (1984: Bioactivities,EstrogenReceptorInteractionsand Plasminogen-Activator-Inducing Activities of Tamoxifen and Hydroxytamoxifen Isomers in MCF-7 Human Breast Cancer Cells.Cancer Res 44:112–119

    PubMed  CAS  Google Scholar 

  • Knabbe C, Lippman ME, Wakefield LM (1987): Evidence that TGF-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417–428

    Article  PubMed  CAS  Google Scholar 

  • Kotoulas IG, Mitropoulos D, Kardamakis E, Dounis A, Michopoulos J (1994): Tamoxifen treatment in male infertibility. I. Effect on spermatozoa. Fert Steril 61:914–922

    Google Scholar 

  • Lipponen PK and Eskelinen MJ (1995): Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121:303–308

    Article  PubMed  CAS  Google Scholar 

  • Locher D, Tang R, Pardo G, Hamlin M (1994): Retinal changes associated with tamoxifen treatment for breast cancer. Invest Ophthalmol Visual Sci 35:1526

    Google Scholar 

  • Loffeld RJLF and Van Weel TF (1993): Tamoxifen for retroperitoneal fibrosis. Lancet 341:382

    Article  PubMed  CAS  Google Scholar 

  • Lopes MCF, Vale MGP, Carvalho AT (1990): Ca2-dependent Binding of Tamoxifen to Calmodulin Isolated from Bovine Brain.Cancer Res 50:2753–2758

    PubMed  CAS  Google Scholar 

  • Mamby CC, Love RR, Feyzi JM (1994): Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women. Breast Ca Res Treat 30:311–314

    Article  CAS  Google Scholar 

  • Mamby CC, Love RR, Lee KE (1995): Thyroid Function Test Changes With Adjuvant Tamoxifen Therapy in Postmenopausal Women With Breast Cancer. J Clin Oncol 13:854–857

    PubMed  CAS  Google Scholar 

  • Manni A, Badger B, Luk G, Wright C, Caplan R, Rockette H, Bartholomew M, Ahmed SR (1988): Role of poly amines in the growth of hormone- responsive experimental breast cancer in vivo. Breast Ca Res Treat 11:231–240

    Article  CAS  Google Scholar 

  • Manni A (1989): Poly amines and Hormonal Control of Breast Cancer Growth. CRC Crit Rev Oncogenesis 1:163–174

    CAS  Google Scholar 

  • Manni A (1994): The role of polyamines in the hormonal control of breast cancer cell proliferation. In: Dickson R and Lippman M (eds): Mammary Tumorigenesis and Malignant Progression. Kluwer Academ Publ pp 209–225

    Google Scholar 

  • Mascarenhas MR, Garcia-e-Costa J, Galvao-Teles A (1994): Medical Therapy in Male Infertility. Prog Reprod Biol Med 16:9–17

    Google Scholar 

  • Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP, Rocherfort H (1994): In vivo Stimulation by Tamoxifen of Cathepsin D RNA Level in Breast Cancer. Europ J Cancer 30A:2049–2053

    Article  CAS  Google Scholar 

  • Millon R, Nicora F, Muller D, Eber M, Klein-Soyer C, Abesassis J (1989): Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin Expl, Metast 7:405–415

    Article  CAS  Google Scholar 

  • Nabai H and Rahbari H (1994): Autoimmune Progesterone Dermatitis Treated with Tamoxifen. Cutis 54:181–182

    PubMed  CAS  Google Scholar 

  • Neal AJ, Evans K, Hoskin PJ (1993): Measurement of the effect of Tamoxifen on bone mineral density. Brit J Radiol 66:49–50

    Google Scholar 

  • Ng R, Kellen JA, Wong AHC (1986): The effect of estrogens and anti-estrogens on plasminogen activator levels in an experimental tumor model. J Nutr Growth Cancer 3:177–181

    CAS  Google Scholar 

  • Nuwaysir EF, Dragan YP, Jefcoate CR, Jordan VC, Pitot HC (1995): Effects of Tamoxifen Administation on the Expression of Xenobiotic Metabolizing Enzymes in Rat Liver. Cancer Res 55:1780–1786

    PubMed  CAS  Google Scholar 

  • O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB (1985): Inhibition of Protein Kinase C by Tamoxifen. Cancer Res 45:2462–2465

    PubMed  Google Scholar 

  • O’Brian CA, Liskamp RM, Solomon DH, Weinstein IB (1986): Triphenylethlenes: A New Class of Protein Kinase Inhibitors.J Natl Cancer Inst 76:1243–1246

    PubMed  Google Scholar 

  • O’Brian CA, Ward NE, Anderson BW (1988a): Role of Specific Interactions Between Protein Kinase C and Triphenylethylenes in Inhibition of the Enzymes. J Natl Cancer Inst 80:1628–1633

    Article  PubMed  Google Scholar 

  • O’Brian CA, Housey GM, Weinstein IB (1988b): Specific and Direct Binding of Protein Kinase C to an Immobilized Tamoxifen Analogue. Cancer Res 48:3626–3629

    PubMed  Google Scholar 

  • O’Brian CA, Ioannides CG, Ward NE, Liskamp RM (1990): Inhibition of Protein Kinase C and Calmodulin by the Geometric Isomers Cis and Trans-Tamoxifen. Biopolymers 29:97–104

    Article  PubMed  Google Scholar 

  • Osborne CK, Boldt DH, Clark GM, Trent JM (183): Effects of Tamoxifen on Human Breast Cancer Cell Cycle Kinetics: Accumulation of Cells in Early G, Phase. Cancer Res 43:3583–3855

    Google Scholar 

  • Pathak AU and Bodell WJ (1994): DNA adduct formation by tamoxifen with rat liver microsomal activation systems. Carcinogenesis 15:529–532

    Article  PubMed  CAS  Google Scholar 

  • Pathak DN, Pongracz K, Bodell WJ (1995): Microsomal and perioxidase activation of 4-hydroxytamoxifen to form DNA adducts. Carcinogenesis 16:11–15

    Article  PubMed  CAS  Google Scholar 

  • Phaneuf S, Europe-Finner GN, MacKenzie IZ, Watson SP, Lopex Bernal A (1995): Effects of oestradiol and tamoxifen on oxytocin-induced phospholipase C activation in human myometrial cells. J Reprod Fertil 103:121–126

    Article  PubMed  CAS  Google Scholar 

  • Pinto HC, Baptista A, Camillo ME, deCosta EB, Valente A, de Moura MC (1995): Tamoxifen-associated steatohepatitis. J Hepatol 23:95–97

    Article  PubMed  CAS  Google Scholar 

  • Pollak M, Powles TJ, Baum M, Sacks N (1993): Tamoxifen used as a chemopreventive agent lowers serum IFG-I levels. Proc AACR 34:255

    Google Scholar 

  • Pongracz K, Pathak DN, Nakamura T, Burlingame AL, Bodell WJ (1995): Activation of the Tamoxifen Derivative Metabolite E to Form DNA Adducts. Cancer Res 55:3012–3015

    CAS  Google Scholar 

  • Recchia F, Sica G, De Fipillis S, Discepoli S, Rea S, Torchio P, Frate, L (1995): Interferon-beta, Retinoids and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study. J Interferon Cytokine Res 15:605–610

    Article  PubMed  CAS  Google Scholar 

  • Repke KRH and Matthes E (1994): Tamoxifen in a Na-antagonistic Inhibitor of Na/K-transporting ATPase from tumour and normal cells. J Enzyme Inhib 8:207–212

    Article  PubMed  CAS  Google Scholar 

  • Rutquist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995): Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary Malignancies.J Natl Cancer Inst 87:645–651

    Article  Google Scholar 

  • Sapino A, Pietribiasi F, Bussolati G, Marchsio PC (1986): Estrogen- and Tamoxifen-induced Rearrangements of Cytoskeletal and Adhesion Structures in Breast Cancer MCF-7 Cells. Cancer Res 46:2526–2531

    PubMed  CAS  Google Scholar 

  • Sartor BM, Sartor O, Flanders KC (1995): Analogous tamoxifen and estrogen effects on trans forming growth factors betal and 2 in rat uterus. Reprod Toxicol 9:225–232

    Article  PubMed  CAS  Google Scholar 

  • Sekeris CE (1991): Hormonal Steroids Act as Tumour Pro motors by Modulating Oncogene Expression. J Cancer Res Clin Oncol 117:96–101

    Article  PubMed  CAS  Google Scholar 

  • Sica G, Natoli C, Marchetti P, Piperno S, Iacobelli S (1984): Tamoxifen- induced membrane alterations in human breast cancer cells. J Steroid Biochem 20:425–428

    Article  PubMed  CAS  Google Scholar 

  • Simon R (1995): Discovering the Truth About Tamoxifen: Problems of Multipicity in Statistical Evaluation of Biomedical Data. J Natl Cancer Inst 87:627–629

    Article  PubMed  CAS  Google Scholar 

  • Sloane B, Herman CJ, Padarathsingh M (1994): Molecular Mechanisms of Progression and Metastasis of Human Tumors. Cancer Res 54:5241–5245

    PubMed  CAS  Google Scholar 

  • Spillane RM and Whitman GJ (1995): Treatment of Retroperitoneal Fibrosis with Tamoxifen.AJR 164:515–516

    PubMed  CAS  Google Scholar 

  • Sthoegar ZM, Bentwich Z, Zinger H, Mozes E (1994): The Beneficial Effect of the Estrogen Antagonist Tamoxifen on Experimental Systemic Lupus Erythematosus. J Rheumat 21:2231–2238

    Google Scholar 

  • Sterzik K, Rosenbusch B, Mogck J, Heyden M, Lichtenberger K (1993): Tamoxifen treatment of oligozoospermia: a re-evaluation of its effects invluding additional sperm function tests. Arch Gyn Obstet 252:143–147

    Article  CAS  Google Scholar 

  • Stevens HP, Ostler LS, Black CM, Jacobs HS, Pustin MHA (1993): Cyclical psoriatic arthritis responding to anti-oestrogen therapy. Brit J Dermatol 129:458–460

    Article  CAS  Google Scholar 

  • Szczensy PJ and Steiner R (1994): Reversibility of visual symptoms in tamoxifen toxicity depends on total cumulative dose. Proc AACR 35:250

    Google Scholar 

  • Thylan S (1995): The beneficial effect of the estrogen antagonist tamoxifen on experimental lupus erythematosus. J Rheumatol 22:1606

    PubMed  CAS  Google Scholar 

  • Toms SA, Casey G, Hercbergs A, Zhoe P, Barnett GH, Barna BP (1995): Tamoxifen-induced p53 independent apoptosis in a human glioblastoma cell line. Proc AACR 36:8

    Google Scholar 

  • Vancutesem PM, Lazarus P, Williams GM (1994): Frequent and Specific Mutations of the Rat p53 Gene in Hepatocarcinomas Induced by Tamoxifen. Cancer Res 54:3864–3867

    Google Scholar 

  • Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C (1994): Somatostatin Analogue Octreotide Enhances the Antineoplastic Effects of Tamoxifen and Ovarectomy on 7,12-Dimethylbenz (alpha)anthracene-induced Rat Mammary Carcinoma. Cancer Res 54:6334–6337

    PubMed  CAS  Google Scholar 

  • White INH, De Matthesis F, Gibbs AH, Lin CK, Wolf CR, Henderson C, Smith LL (1995): Species Differences in the covalent binding of tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochem Pharmacol 49:1035–1042

    Article  PubMed  CAS  Google Scholar 

  • Wright CDP and Compston JE (1995): Oestrogen or anti-oestrogen in bone? Quart J Med 88:307–310

    CAS  Google Scholar 

  • Yu H, Diamandis EP, Zarghami N, Grass L (1994): Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Ca Res Treat 32:291–300

    Article  CAS  Google Scholar 

  • Yu H, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P (1995): Prostate-specific Antigen Is a New Favorable Prognostic Indicator for Women with Breast Cancer. Cancer Res 55:2104–2110

    PubMed  CAS  Google Scholar 

  • Zhang JJ, Jacob TJC, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, Gill DR, Hyde SC, Trezise AEO, Higgins CF (1994): Tamoxifen Blocks Chloride Channels. A Possible Mechanism for Cataract Formation. J Clin Invest 94:1690–1697

    Article  PubMed  CAS  Google Scholar 

  • Zhang JJ, Jacob TJC, Hardy SP, Higgins CR, Valverde MA (1995): Lens opacidication by antiestrogens: Tamoxifen vs ICI 182,780. Brit J Pharmacol 115:1347–1348

    CAS  Google Scholar 

  • Zimniski SJ and Warren RC (1993): Induction of Tamoxifen-dependent Rat Mammary Tumors.Cancer Res 53:2937–2939

    PubMed  CAS  Google Scholar 

References

  • Ahlgren JD, Ellison N, Lokich J, Ueno W, Gottlieb R, Laluna F, Wampler G, Fryer J, Fryer D (1993): High-dose tamoxifen: Extended palliation in patients with chemoresistant epithelial ovarian cancer. Proc Amer Soc Clin Oncol 12:258

    Google Scholar 

  • Bajetta E, Zampino M, Nole F, Zilembo N (1993): Tamoxifen does not improve response when added to chemotherapy in metastatic melanoma. Proc Amer Soc Clin Oncol 12:393

    Google Scholar 

  • Baltuch G, Shenouda G, Langleben A, Villemure JG (1993): High Dose Tamoxifen in the Treatment of Recurrent High Grade Glioma. Can J Neurol Sci 20:168–170

    PubMed  CAS  Google Scholar 

  • Bruix J, Castells A, Bru C, Ayuso MC, Boix L, Roca M, Rodes J (1994): Treatment of advanced hepatocellular carcinoma with tamoxifen. Hepatology 20:297A

    Article  Google Scholar 

  • Cheng AL, Chen YC, Sheu JC, Chen BR, Hsu HC, Lkai MY, Yeh KH, Chen DS (1993): Chronic oral VP-16 plus tamoxifen in the treatment of far- advanced hepatocellular carcinoma. Proc Amer Soc Clin Oncol 12:204

    Google Scholar 

  • Chmielowska E, Potemski P, Pluzanska A (1995): Three-drug combination of cisplatin, dacarbazine and tamoxifen in metastatic malignant melanoma. J Clin Oncol 13:2146

    PubMed  CAS  Google Scholar 

  • Constanzi J, Chun H, Mittelman A, Puccio C, Coombe N, Panella T, Mesches D, Shogen K, Mikulski S (1994): Phase I/II clinical trial of onconase plus tamoxifen in patients with advanced pancreatis carcinoma. Proc Amer Soc Clin Oncol 13:205

    Google Scholar 

  • Dean PA, Penna C, Camillari MJ, Dozois RR (1994): Prospective evaluation of the association of sulindac-tamoxifen in the treatment of abdominal desmoid tumors in familial adenomatous polyposis. Gastroent Clin Biol 18:B313

    Google Scholar 

  • Garcia-Pascual L, Millan M, Anglada J, Garau (1993): Tamoxifen failure in medullary thyroid carcinoma. Tumori 79:357–358

    PubMed  CAS  Google Scholar 

  • Gasparini G (1994): Tamoxifen and Chemotherapy in the Treatment of Metastatic Melanoma: Are There Other Possible Mechanisms Explaining Their Potentiation? J Clin Oncol 12:1994–1995

    PubMed  CAS  Google Scholar 

  • Goldin BR (1994): Nonsteroidal Estrogens and Estrogen Antagonists: Mechanism of Action and Health Implications.J Natl Cancer Inst 86:1741–1742

    Article  PubMed  CAS  Google Scholar 

  • Grenman R, Virolainen E, Shapira A, Carey T (1987): In Vitro Effects of Tamoxifen on UM-SCC Head and Neck Cancer Cell Lines: Correlation with the Estrogen and Progesterone Content. Int J Cancer 39:77–81

    Article  PubMed  CAS  Google Scholar 

  • Gouyon B, Ducreux M, Rougier P, Berthelot G, Lasser P (1994): Desmoid tumour: partial response with tamoxifen therapy.Gastroent Clin Biol 18:792–794

    PubMed  CAS  Google Scholar 

  • Hoelting T, Siperstein AE, Duh QY, Clark OH (1995): Tamoxifen Inhibits Growth, Migration and Invasion of Human Follicular and Papillary Thyroid Cancer Cells in Vitro and in Vivo. J Clin End Metabol 80:308–313

    Article  CAS  Google Scholar 

  • Horimi T, Morita S, Takasaki M, Yormitu Y, Takahashi I (1993): Hormone therapy of Tamoxifen in resectable carcinoma of the pancreas. J Jap Soc Cancer Ther 28:494

    Google Scholar 

  • Iwasaki K, Toms SA, Barnett GH, Estes ML, Gupta MK, Barna BO (1995): Inhibitory effects of tamoxifen and tumour necrosis factor alpha on human glioblastoma cells. Cancer Immunol Immunother 40:228–234

    Article  PubMed  CAS  Google Scholar 

  • Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995): Use of Tamoxifen for Breast Cancer: Twenty-Eight Years Later. J Clin Oncol 13:513–529

    PubMed  CAS  Google Scholar 

  • Laffite C, Li YJ, Ameri A, Chauveinc L, Poisson M, Delattre JY (1994): Treatment of Malignancy Supratentorial Gliomas With the Association of BCNU and Tamoxifen: A Phase II Study. Neurology 44:A308

    Google Scholar 

  • Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF, Miller WR (1993): Growth inhibition of ER-positive ovarian carcinoma cells by antiestrogens in vitro and in vivo. Proc AACR 34:244

    Google Scholar 

  • Lazo JS, Schwartz PE, MacLusky NJ, Labaree DC, Eisenfeld AJ (1984): Antiproliferative Actions of Tamoxifen in Human Ovarian Carcinomas. Cancer Res 44:2266–2271

    CAS  Google Scholar 

  • MacNeil S, Wagner M, Rennie IG (1994a): Investigation of the role of signal transduction in attachment of ocular melanoma cells to matrix proteins: inhibition of attachment of calmodulin antagonists including tamoxifen. Clin Exp Metast 12:375–384

    Article  CAS  Google Scholar 

  • MacNeil S, Wagner M, Rennie IG (1994b): Tamoxifen Inhibition of Ocular Melanoma Cell Attachment to Matrix Proteins. Pigment Cell Res 7:222–226

    Article  PubMed  CAS  Google Scholar 

  • Piantelli M, Maggiano N, Ricci R, Larocca LM, Capelli A, Scambia G, Isola G, Natali PG, Ranelletti FO (1995): Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 105:248–253

    Article  PubMed  CAS  Google Scholar 

  • Pienta KJ, Replogie T, Lehr JE (1995): Inhibition of prostate cancer growth by vinblastine and tamoxifen. Prostate 26:270–274

    Article  PubMed  CAS  Google Scholar 

  • Pons M, Hetherington M, Massey V, Hanson EJ, Egelhoff J, Zwick D, Convy L, Freemand A (1994): Preliminary Results: Recurrent Intrinsic Brainstem Gliomas of Childhood Respond to Tamoxifen.Ann Neurol 36:514

    Google Scholar 

  • Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA (1994): Modification of the Effect of Tamoxifen, cis-Platin, DTIC and Interferon-alpha2b on Human Melanoma Cells in Culture by a Mixture of Vitamins. Nutr Cancer 22:233–245

    Article  PubMed  CAS  Google Scholar 

  • Pu YS, Hsieh TS, Tsai TC, Cheng AL, Hsieh CY, Su IJ, Lai MK (1995): Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154:601–605

    Article  PubMed  CAS  Google Scholar 

  • Punt CJA, Tytgat JH, van Liessum PA, Gerard B (1995): Fotemustin and Tamoxifen Combination Therapy in Metastatic Malignant Melanoma. A Phase II Study. Europ J Cancer 31A: 421–422

    Article  CAS  Google Scholar 

  • Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT (1995): High-Dose Antiepileptic Drugs. Epilepsy 36:513–515

    Article  CAS  Google Scholar 

  • Reintgen D, Saba H (1993): Chemotherapy for Stage 4 Melanoma: A Three- Year Experience with Cisplatin, DTIC, BCNU and Tamoxifen. Sem Surg Oncol 9:251–255

    CAS  Google Scholar 

  • Rosenberg L, Barkun AN, Denis MH, Pollack M (1995): Low Dose Octreotide and Tamoxifen in the Treatment of Adenocarcinoma of the Pancreas. Cancer 75:23–28

    Article  PubMed  CAS  Google Scholar 

  • Satyaswaroop PG, Zaino RJ, Mortel R (1984): Estrogen-Like Effects of Tamoxifen on Human Endometrial Carcinoma Transplanted into Nude Mice. Cancer Res 44:4006–4010

    PubMed  CAS  Google Scholar 

  • Shapira A, Virolainen E, Jameson J (186): Growth inhibition of laryngeal UM- SCC cell lines with Tamoxifen, comparison with effects on the MCF-7 breast cancer line. Arch Otolaryngol Head Neck Surg 112:1151–1158

    Google Scholar 

  • Shenouda G, Preul M, Langleben A, Villemure JG, Bahary JP, Wainer I, Pollak M, Leyland-Jones B, Tsatoumas A, Choi A (1994): A phase I/II trial of high dose tamoxifen in patients with recurrent high grade cerebral astrocytomas. J Neuro Oncol 19:181

    Google Scholar 

  • Sismondi P, Biglia N, Volpi E, Gail M, DeGrandis T (1994): Tamoxifen and Endometrial Cancer. Ann NY Acad Sci 734:310–321

    Article  PubMed  CAS  Google Scholar 

  • Spitler L, Good J, Jacobs M, Gilyon K (1994): The use of high-dose tamoxifen to potentiate the anti-tumor effects of cytotoxic chemotherapy in patients with metastatic melanoma. Proc Atner Soc Clin Oncol 13:397

    Google Scholar 

  • Sridhar KS, Benedetto P, Otrakji CL, Charyulu KK (1989): Response of Eccrine Adenocarcinoma to Tamoxifen.Cancer 64:366–370

    Article  PubMed  CAS  Google Scholar 

  • Toms SA, Casey G, Hercberg A, Zhou P, Barnett GH, Barna BP (1995): Tamoxifen-induced p-53 independent apoptosis in a human glioblastoma cell line. Proc AACR 36:8

    Google Scholar 

  • Urba S, Carey T, Kudla-Hatch V (1990): Tamoxifen therapy in patients with recurrent laryngeal squamouc carcinoma. Laryngoscope 100:76–78

    Article  PubMed  CAS  Google Scholar 

  • Vargas Roig LM, Lotfi H, Olcese JE, Lo Castro G, Ciocca DR (1993): Effects of Short-Term Tamoxifen Administration in Patients with Invasive Cervical Carcinoma. Anticancer Res 13:2457–2464

    PubMed  CAS  Google Scholar 

  • Vertosick FT, Selker RG, Arena V (1994): A Dose-Escalation Study of Tamoxifen Therapy in Patients with Recurrent Glioblastoma Multiforme. J Neurosurg 80:385A

    Google Scholar 

  • Wada T, Nishiyama K, Maeda M, Hara S, Tanaka N, Yasutomi M, Kurita T (1995): Combined Chemoednocrine Treatment with Tegafur and Tamoxifen for Advanced Renal Cell Carcinoma.Anticancer Res 15:1581–1584

    PubMed  CAS  Google Scholar 

  • Wong A, Chan A, Arthur K (1987): Tamoxifen Therapy with Unresectable Adenocarcinoma of the Pancreas. Ca Treat Rep 71:749–750

    CAS  Google Scholar 

  • Zanboni A, Meriggi F, Arcangeli G, Alghisi A, Huscher C, Marini G (1994): Leuprolide and Tamoxifen in the Treatment of Pancreatic Cancer. A Phase II Study. Europ J Cancer 30A:128

    Article  Google Scholar 

Download references

Authors
  1. J. A. Kellen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 89 Rameau Drive, Toronto, Ontario, M2H 1T6, Canada

    John A. Kellen

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Birkhäuser Boston

About this chapter

Cite this chapter

Kellen, J.A. (1996). Introduction: The Enigma of Tamoxifen. In: Kellen, J.A. (eds) Tamoxifen. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4092-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4092-1_1

  • Publisher Name: Birkhäuser Boston

  • Print ISBN: 978-1-4612-8648-6

  • Online ISBN: 978-1-4612-4092-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation